Its absence in biopsies from patients with amyloidosis, other GN, or healthy controls established DNAJB9 as the first biomarker for FGN, allowing differentiation from amyloidosis and other glomerular diseases [15,16]. Here, DNAJB9 is linked to amyloidosis.